• 1
    Jakowlew SB. Transforming growth factor-β in cancer metastasis. Cancer Metastasis Rev 2006; 25: 43557.
  • 2
    Bierie B,Moses HL. Tumour microenvironment: TGF β: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6: 50620.
  • 3
    Levy L,Hill CS. Alterations in components of the TGF-β superfamily signalling pathways in human cancer. Cytokine Growth Factors Rev 2006; 17: 4158.
  • 4
    Cox A,Dunning AM,Garcia-Closas M,Balasubramanian S,Reed MW,Pooley KA,Scollen S,Baynes C,Ponder BA, et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 2007; 39: 3528.
  • 5
    Scola L,Vaglica M,Crivello A,Palmeri L,Forte GI,Macaluso MC,Giacalone A,Di Noto L,Bongiovanni A,Raimondi C,Accardo A,Verna R, et al. Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma. Ann N Y Acad Sci 2006; 1089: 98103.
  • 6
    Kang HG,Chae MH,Park JM,Kim EJ,Park JH,Kam S,Cha SI,Kim CH,Park RW,Park SH,Kim YL,Kim IS, et al. Polymorphisms in TGF-β1 gene and the risk of lung cancer. Lung Cancer 2006; 52: 17.
  • 7
    Wei YS,Zhu YH,Du B,Yang ZH,Liang WB,Lv ML,Kuang XH,Tai SH,Zhao Y,Zhang L. Association of transforming growth factor-β1 gene polymorphisms with the genetic susceptibility to nasopharyngeal carcinoma. Clin Chim Acta 2007; 380: 1659.
  • 8
    Mazur G,Bogunia-Kubik K,Wrobel T,Kuliczkowski K,Lange A. TGF-β1 gene polymorphisms influence the course of the disease in non-Hodgkin's lymphoma patients. Cytokine 2006; 33: 1459.
  • 9
    Kaklamani VG,Hou N,Bian Y,Reich J,Offit K,Michel LS,Rubinstein WS,Rademaker A,Pasche B. TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies. J Clin Oncol 2004; 22: 7568.
  • 10
    Pasche B,Kolachana P,Nafa K,Satagopan J,Chen YG,Lo RS,Brener D,Yang D,Kirstein L,Oddoux C,Ostrer H,Vineis P, et al. TGF β R-I (6A) is a candidate tumor susceptibility allele. Cancer Res 1999; 59: 567882.
  • 11
    Pasche B,Knobloch TJ,Bian Y,Liu J,Phukan S,Rosman D,Kaklamani V,Baddi L,Siddiqui FS,Frankel W,Prior TW,Schuller DE, et al. Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA 2005; 294: 163446.
  • 12
    Kaklamani VG,Hou N,Bian Y,Reich J,Offit K,Michel LS,Rubinstein WS,Rademaker A,Pasche B. TGFBR1*6A and the cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol 2003; 21: 323643.
  • 13
    García-Closas M,Malats N,Silverman D,Kogevinas M,Hein DW,Tardón A,Serra C,Carrato A,García-Closas R,Lloreta J,Castaño-Vinyals G,Yeager Y, et al. NAT2 slow acetylation. GSTM1 null genotype, and risk of bladder cancer: results from the Spanish bladder cancer study and meta-analyses. Lancet 2005; 366: 64959.
  • 14
    Reuter VE,Epstein JI,Amin MB,Mostofi FK. The WHO/IUSP consensus classification of urothelial (transitional cell) neoplasms: continued discussion. Hum Pathol 1999; 30: 87980.
  • 15
    Hernández S,López-Knowles E,Lloreta J,Kogevinas M,Amorós A,Tardón A,Carrato A,Serra C,Malats N,Real FX;on behalf of the EPICURO Study Investigators. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006; 24: 366471.
  • 16
    García-Closas M,Malats N,Real FX,Yeager M,Welch R,Silverman D,Kogevinas M,Dosemeci M,Figueroa JD,Chatterjee N,Tardón A,Serra C, et al. Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet 2007; 3: 028793.
  • 17
    Sole X,Guino E,Valls J,Iniesta R,Moreno V. SNPStats: a web toolfor the analysis of association studies. Bioinformatics 2006; 22: 19289.
  • 18
    Tregouet DA,Garelle V. A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. Bioinformatics 2007; 23: 10389.
  • 19
    Benjamini Y,Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 57: 289300.
  • 20
    Awad MR,El-Gamel A,Hasleton P,Turner DM,Sinnott PJ,Hutchinson IV. Genotypic variation in the transforming growth factor-β 1 gene: association with transforming growth factor-β 1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998; 66: 101420.
  • 21
    Suthanthiran M,Li B,Song JO,Ding R,Sharma VK,Schwartz JE,August P. Transforming growth factor-β 1 hyperexpression in African-American hypertensives: a novel mediator of hipertension and/or target organ damage. Proc Natl Acad Sci USA 2000; 97: 347984.
  • 22
    Syrris P,Carter ND,Metcalfe JC,Kemp PR,Grainger DJ,Kaski JC,Crossman DC,Francis SE,Gunn J,Jeffery S,Heathcote K. Transforming growth factor β1 gene polymorphisms and coronary artery disease. Clin Sci 1998; 95: 65967.
  • 23
    Skoglund J,Song B,Dalen J,Dedorson S,Edler D,Hjern F,Holm J,Lenander C,Lindforss U,Lundqvist N,Olivecrona H,Olsson L, et al. Lack of an association between the TGFBR16A variant and colorectal cancer risk. Clin Cancer Res 2007; 13: 374852.
  • 24
    van Tilborg AAG,de Vries A,Zwarthoff EC. The chromosome 9q genes TGFBR1. TSC1 and ZNF189 are rarely mutated in bladder cancer. J Pathol 2001; 194: 7680.